Small-cap stocks can be outstanding growth vehicles for the buy-and-hold crowd. On balance, stocks with market caps below $2 billion have trounced the broader markets over the past two decades. The downside is that small-cap stocks tend to be on the volatile side and there's also a far greater chance of outright failure when it comes to this risky group of equities.
Which small-cap stocks should growth-oriented investors consider adding to their portfolios this month? Catalyst Pharmaceuticals (NASDAQ: CPRX), EyePoint Pharmaceuticals (NASDAQ: EYPT), and Geron (NASDAQ: GERN) are three up-and-coming biotechs that might be worth buying right now. Here's a rundown of the key facts and figures for each company.
Image source: Getty Images.